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Guidelines summarize and evaluate all evidence available, at
the time of the writing process, on a particular issue.
Guidelines and recommendations should help physicians to
make decisions in their daily practice. The level of evidence
and the strength of recommendation of particular treatment
options were weighed and graded according to predeﬁned
scales, as outlined in Tables 1 and 2.
2. Introduction
2.1. The magnitude of the problem
These present guidelines are intended for physicians and
collaborators involved in the pre-, peri-, and post-operative
care of patients undergoing non-cardiac surgery. The guide-
lines focus on the cardiovascular management of patients in
whom heart disease is a potential source of complications
during non-cardiac surgery. The risk of perioperative compli-
cations depends on the condition of the patient before surgery,
the prevalence of comorbidities, and the urgency, magnitude,
type, and duration of the surgical procedure. More speciﬁcally,
cardiac complications can arise in patients with documentedor asymptomatic ischaemic heart disease, left ventricular
dysfunction, valvular heart disease, and arrhythmias, who
undergo surgical procedures that are associated with pro-
longed haemodynamic and cardiac stress.
Worldwide, non-cardiac surgery is associated with an
average overall annual complication rate of between 7% and
11% and a mortality rate between 0.8% and 1.5% depending on
safety precautions. Up to 42% of these are caused by cardiac
complications. When applied to the population in the
European Union member states, these ﬁgures translate into
at least 167,000 cardiac complications, of which 19,000 are life-
threatening, due to non-cardiac surgical procedures annually.
2.2. Purpose and organization
The guidelines recommend a practical, stepwise evaluation
that integrates clinical risk factors and test results with the
estimated stress of the planned surgical procedure. This
results in an individualized cardiac risk assessment, with the
opportunity to initiate medical therapy, coronary interven-
tions, and speciﬁc surgical and anaesthetic techniques in
order to optimize the patient's perioperative condition. The
patients with stable heart disease can undergo a low and
intermediate risk surgery without additional evaluation.
Selected patients require evaluation by a team of integrated
multidisciplinary specialists including anaesthesiologists,
Table 2 – Levels of evidence.
Level of   
evidence A 
Data derived from  multiple  random ized cli nical trials or meta-ana lys es. 
Level of   
evidence B 
Data deri ved fr om a single rand omized  clinical  trials  or  lar ge non-randomized  stu dies. 
Level of  
evidence C 
Consensus of  opinion  of the  ex perts  and/ or  smal l studie s, retro specti ve stud ies re gistrie s. 
Table 1 – Classes of recommendations.
Classes of
recomentaons
Deﬁnions Suggested
wording to use
Class I Evidence  or  gen eral agreement that  th e given trea tmen t or  procedur  eis  benef icial,  us eful,  effe ctive . Is  rec omm ended/ is 
indicated 
Class II  Conflicting  evid ence and/or a  
diverge nce  of op inion  ab out the  
usefulness/efficacy of  the given  
treatment or  pro cedure . 
    Class  IIa  Weight  of  evidence/opinion is  in   
favour of us efulness/eff icacy.  
Should be  considere d 
    Class  IIb Usefulness/ efflcacy ts  less  well  
establlshed by  ev idence/opinion . 
May be cons ider ed 
Class III  Evidence  or  gen eral agreement that  th e given trea tment or  procedur e is  not  use ful/  effective  and  in  same 
cases may  be har mful l 
Is not  rec ommended 
c o r e t v a s a 5 7 ( 2 0 1 5 ) e 1 9 0 – e 2 1 3 e193cardiologists, and surgeons, and when appropriate an extend-
ed team. Anaesthesiologists will usually coordinate the pre-
operative evaluation. Selected patients include those with
suspected or known cardiac disease with sufﬁcient complexity
to carry a potential perioperative risk (e.g. congenital heart
disease, unstable symptoms, or low functional capacity)
patients in whom pre-operative medical optimization is
expected to reduce peri-operative risk before low- and
intermediate-risk surgery, and patients with known or high-
risk of cardiac disease undergoing high-risk surgery.
3. Pre-operative evaluation
3.1. Surgical risk for cardiac events
Cardiac complications after non-cardiac surgery depend on
patient-related risk factors, on the type of surgery, and on the
circumstances under which it takes place. Surgical factors that
inﬂuence cardiac risk are related to the urgency, invasiveness,
type, and duration of the procedure, as well as the change in
body core temperature, blood loss, and ﬂuid shifts. Every
operation elicits a stress response. This response is initiated by
tissue injury and mediated by neuro-endocrine factors, and
may induce sympatho-vagal imbalance. Fluid shifts in the
perioperative period add to the surgical stress. This stress
increases myocardial oxygen demand. Surgery also causesalterations in the balance between prothrombotic and
ﬁbrinolytic factors, potentially resulting in increased coro-
nary thrombogenicity.
With regard to cardiac risk, surgical interventions—which
include open or endovascular procedures—can be broadly
divided into low-risk, intermediate-risk, and high-risk groups,
with estimated 30-day cardiac event rates (cardiac death and
myocardial infarction) of <1%, 1–5%, and >5%, respectively in
Table 3.
3.2. Type of surgery
The wide variety of surgical procedures, in a myriad of
different contexts, makes difﬁcult the assignation of a speciﬁc
risk of a major adverse cardiac event to each procedure. When
alternative methods to classical open surgery are considered,
either through endovascular or less-invasive endoscopic
procedures, the potential trade-offs between early beneﬁts
due to reduced morbidity and mid- to long-term efﬁcacy need
to be taken into account.
3.2.1. Endovascular vs. open vascular procedures
Vascular interventions are of speciﬁc interest, not only
because they carry the highest risk of cardiac complications,
but also because of the many studies showed that this risk can
be inﬂuenced by adequate perioperative measures in these
patients.
Table 3 – Surgical risk estimate according to type of surgery or intervention.a,b
Low-risk:  < 1% Intermedi ate-risk:  1-5% Hight -ri sk:  >5%
Superfici al su rgery 
Breast
Denta l 
Endocrine:thyroid 
Eye
Reconstru ctiv e 
Caro tid asymptomatic  (CEA or  CAS ) 
Gynaecology : minor  
Orthopaedi c: minor (menisce ctomy) 
Urological: minor  (t ransure thral  resec tion  of the pros tate) 
Intraperitoneal: splenect omy,  hiatal  hernia  repair, 
cholecystectomy 
Carotid  symptomatic  (C EA or CAS)   
Periphera1  arterial  angiopla sty  
Endovascular aneury sm repair  
Head and  neck surgery 
Neurological or  or thopaedic : major (hip  and  spine  
surgery)
Urological or  gy naecological : major  
Renal  transpla nt 
Intra-th oraci c: non-major 
Aortic and  major  vascular  surgery   
Open lo wer  li mb revasculari zation  or   
ampu tation  or  thromboe mbolec tomy  
Duodeno-pancreatic  surger y 
Liver resectio n,  bile  duc t surgery   
Oesophagec tomy 
Repair  of  perfor ated  bo wel   
Adrenal resectio n 
Total cystect omy  
Pne umone ctomy 
Pulmonary  or  liver  transplant  
CAS, carotid artery stenting; CEA, carotid endarterectomy.
a Surgical risk estimate is a broad approximation of 30-day risk of cardiovascular death and myocardial infarction that takes into account only
the speciﬁc surgical intervention, without considering the patient's comorbidities.
b Adapted from Glance et al.
c o r e t v a s a 5 7 ( 2 0 1 5 ) e 1 9 0 – e 2 1 3e1943.2.2. Open vs. laparoscopic or thoracoscopic procedures
Laparoscopic procedures, compared with open procedures,
have the advantage of causing less tissue trauma and
intestinal paralysis, resulting in less incisional pain, better
post-operative pulmonary function, signiﬁcantly fewer wall
complications, and diminished post-operative ﬂuid shifts
related to bowel paralysis. Compared with open surgery,
cardiac risk in patients with heart failure is not reduced in
patients undergoing laparoscopy (Table 4).
3.3. Functional capacity
Determination of functional capacity is a pivotal step in pre-
operative cardiac risk assessment and is measured in
metabolic equivalents (METs). Exercise testing provides an
objective assessment of functional capacity. FunctionalTable 4 – Recommendations on the selection of surgical
approach and its impact on risk.
AAA, abdominal aortic aneurysm; EVAR, endovascular aortic
reconstruction.
aClass of recommendation.
bLevel of evidence.capacity can be estimated from the ability to perform the
activities of daily living in Fig. 1.
The inability to climb two ﬂights of stairs or run a short
distance (<4 METs) indicates poor functional capacity and is
associated with an increased incidence of post-operative
cardiac events. Notably, when functional capacity is high,
the prognosis is excellent, even in the presence of stable IHD or
risk factors otherwise, when functional capacity is poor or
unknown, the presence and number of risk factors in relation
to the risk of surgery will determine pre-operative risk
stratiﬁcation and perioperative management.
3.4. Risk indices
For two main reasons, effective strategies aimed at reducing
the risk of perioperative cardiac complications should
involve cardiac evaluation, using medical history before
the surgical procedure. Firstly, patients with an anticipated
low cardiac risk—after thorough evaluation—can be operat-
ed on safely without further delay. It is unlikely that risk-
reduction strategies will further reduce the perioperative
risk. Secondly, risk reduction by pharmacological treatment
is most cost-effective in patients with a suspected increased
cardiac risk. Additional non-invasive cardiac imaging
techniques are tools to identify patients at higher risk;
however, imaging techniques should be reserved for those
patients in whom test results would inﬂuence and change
management.
3.5. Biomarkers
Cardiac troponins T and I (cTnT and cTnI) are the preferred
markers for the diagnosis of myocardial infarction. Assess-
ment of cardiac troponins in high-risk patients, both before
and 48–72 h after major surgery, may therefore be consid-
ered.
Pre-operative BNP and NT-proBNP levels have additional
prognostic value for long-term mortality and for cardiac events
after major non-cardiac vascular surgery.
Functional  ca pacity
1 MET    Can you… 4 METs Can you…
Take care  of yourse lf? 
Eat, dress, 
 or  use the toilet? 
Walk indo ors  
arou nd  
the ho use? 
Walk 100 m  
on leve l gro und  
at 3 to  5 km per h? 
Climb  two f lights of s tairs  
Do heavy work  
arou nd the house li ke  
scrubbin g flo ors  of  liftin g  
or mov ing he avy  
furnit ure? 
Participate  in stren uous  
sports  li ke sw imming,   
sing les  tenn is, football ,  
basketball , or skii ng? 
4 METs 
Greater 
than 
10 METs 
Fig. 1 – Functional capacity. MET, metabolic equivalent; km per h, kilometres per hour.
Table 5 – Recommendations on cardiac risk stratification.
BNP, B-type natriuretic peptide; NT-proBNP, N-terminal pro-brain
natriuretic peptide; NSQIP, National Surgical Quality Improvement
Program.
aClass of recommendation.
bLevel of evidence.
c o r e t v a s a 5 7 ( 2 0 1 5 ) e 1 9 0 – e 2 1 3 e195Assessment of serum biomarkers for patients undergoing
non-cardiac surgery cannot be proposed for routine use, but
may be considered in high-risk patients (METs ≤4 or with a
revised cardiac risk index value >1 for vascular surgery and >2
for non-vascular surgery) (Table 5).
3.6. Non-invasive testing
Pre-operative non-invasive testing aims to provide informa-
tion on three cardiac risk markers: LV dysfunction, myocardial
ischaemia, and heart valve abnormalities, LV function is
assessed at rest, and various imaging methods are available.
For detection of myocardial ischaemia, exercise ECG and non-
invasive imaging techniques may be used. Routine chest X-ray
before non-cardiac surgery is not recommended.
3.6.1. Non-invasive testing of cardiac disease
3.6.1.1. Electrocardiography. The 12-lead ECG is commonly
performed as part of pre-operative cardiovascular risk assess-
ment in patients undergoing non-cardiac surgery. In IHD
patients, the pre-operative ECG offers important prognostic
information and is predictive of long-term outcome, indepen-
dent of clinical ﬁndings and perioperative ischaemia (Table 6).
3.6.1.2. Assessment of left ventricular function. Routine echo-
cardiography is not recommended for the pre-operative
evaluation of ventricular function but may be performed in
Table 6 – Recommendations on routine pre-operative
ECG.
ECG, electrocardiography.
aClass of recommendation.
bLevel of evidence.
Table 7 – Recommendations on resting echocardiography
in asymptomatic patients without signs of cardiac
disease or electrocardiographic abnormalities.
aClass of recommendation.
bLevel of evidence.
c o r e t v a s a 5 7 ( 2 0 1 5 ) e 1 9 0 – e 2 1 3e196asymptomatic patients with high surgical risk. Pre-operative
LV systolic dysfunction, moderate-to-severe mitral regurgita-
tion, and increased aortic valve gradients are associated with
major cardiac events (Table 7).
3.6.2. Non-invasive testing of ischaemic heart disease
Myocardial ischaemic response at low exercise workloads is
associated with a signiﬁcantly increased risk of perioperative
and long-term cardiac events. In contrast, the onset of
myocardial ischaemia at high workloads is associated with
only a minor risk increase, but higher than a totally normal
test. Pharmacological stress testing with either nuclearTable 8 – Recommendations on imaging stress testing before s
MET, metabolic equivalent.
aClass of recommendation.
bLevel of evidence.perfusion imaging or echocardiography is more suitable in
patients with limited exercise tolerance (Table 8).
Interpretation of non-invasive stress test results: patients
without stress-induced ischaemia, or with mild-to-moderate
ischaemia suggestive of one- or two-vessel disease, can
proceed with the planned surgical procedure.
3.7. Invasive coronary angiography
In patients with extensive stress-induced ischaemia, as
assessed by non-invasive testing, individualized peri-opera-
tive management is recommended, taking into consideration
the potential beneﬁt of the proposed surgical procedure
compared with the predicted adverse outcome. Also, the
effect of medical therapy and/or coronary revascularization
must be assessed, not only for immediate post-operative
outcome, but also for long-term follow-up. In patients referredurgery in asymptomatic patients.
Table 9 – Recommendations on pre-operative coronary angiography.
NSTE-ACS, non-ST-segment elevation acute coronary syndromes.
aClass of recommendation.
bLevel of evidence.
c o r e t v a s a 5 7 ( 2 0 1 5 ) e 1 9 0 – e 2 1 3 e197for percutaneous coronary artery intervention, the initiation
and duration of anti-platelet therapy will interfere with the
planned surgical procedure (Table 9).
4. Risk-reduction strategies
4.1. Pharmacological
4.1.1. Beta-blockers
Beta-blockers should be continued when prescribed for IHD or
arrhythmias. Beta-blockers should not be withdrawn inpatients treated for stable heart failure due to LV systolic
dysfunction.
Beta1-selective blockers without intrinsic sympathomi-
metic activity are favoured and evidence exists that atenolol
and bisoprolol are superior to metoprolol.
Beta-blocker dose should be slowly uptitrated and tailored
to appropriate heart rate and blood pressure targets, requiring
that treatment be initiated ideally more than 1 day (when
possible at least 1 week and up to 30 days) before surgery
(Table 10).
In patients with normal renal function, atenolol treatment
should start with a 50 mg daily dose, then adjusted before
Table 10 – Recommendations on beta-blockers.
Recomm endati ons Classa Levelb
Peri-ope rative  cont inu ation of be ta- blockers  is  re comme nded in
patients curr ently receiving th is
medication . I B
Pre-o per ative initia tion of  beta-
bloc kers ma y be  considered  in patient s sche duled fo r high-r isk su rgery and  who hav e   2 cli nical 
risk factors  or  ASA status    3. IIb B
Pre-o per ative initia tion of  beta-
bloc kers ma y be  considered  in patient s who  have kno wn IHD or  myocar dial  ischaemia .
IIb B
When oral beta- blockade is
initiated in patients who und ergo
non-cardiac surgery, th e use of  aten olol  or  bi soprol ol as  a fi rst cho ice  may  be  cons idered. IIb B
Initiatio n of  peri-o perative hi gh-
dose beta-blo ckers wi thout titration is not recomm ended. III B
Pre-o per ative initia tion of  beta-
bloc kers is not  recomm ended  in patients sche duled for low -risk  surg ery. III B
ASA, American Society of Anesthesiologists; IHD, ischaemic heart disease.
aClass of recommendation.
bLevel of evidence.
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systolic blood pressure >100 mmHg. Intra-operative mean
arterial pressure should remain above 55 mmHg.
4.1.2. Statins
Patients with non-coronary atherosclerosis should receive
statin therapy for secondary prevention, irrespective of non-
cardiac surgery. Statins also induce coronary plaque stabiliza-
tion statins and may be favoured to bridge the period
immediately after surgery when oral intake is not feasible.
In patients not previously treated, statins should ideally be
initiated at least 2 weeks before intervention and continued for
at least 1 month after surgery (Table 11).
4.1.3. Nitrates
Perioperative use of nitro-glycerine may pose haemodynamic
risk to patients.
4.1.4. Angiotensin-converting enzyme inhibitors and
angiotensin-receptor blockers
ACEIs withdrawal should be considered 24 h before surgery
when they are prescribed for hypertension. They should be
resumed after surgery as soon as blood volume and pressure
are stable. In patients with LV systolic dysfunction, who are ina stable clinical condition, it seems reasonable to continue
treatment with ACEIs under close monitoring during the
perioperative period (Table 12).
4.1.5. Calcium channel blockers
The continuation or introduction of heart rate-reducing
calcium channel blockers may be considered in patients
who do not tolerate beta-blockers. Calcium channel blockers
should be continued during non-cardiac surgery in patients
with vasospastic angina.
4.1.6. Alpha2 receptor agonists
Alpha2 receptor agonists should not be administered to
patients undergoing non-cardiac surgery.
4.1.7. Diuretics
Diuretics for hypertension should be continued to the day of
surgery and resumed orally when possible. Diuretic treatment
—if necessary to control heart failure—should be continued to
the day of surgery and resumed orally when possible. The use
of K+ and Mg2+-sparing aldosterone antagonists reduces the
risk of mortality in severe heart failure. Special attention
should be given to patients taking diuretics and patients prone
to developing arrhythmias.
Table 11 – Recommendations on statins.
Recommendation s Clas sa Levelb
Peri- operativ e con tinuation  of  statins  is rec ommende d, favou ring sta tins with a long half-li fe
or extended-re lease formulation.
I C
Pre- operative  initiat ion  of  sta tin  therapy  shou ld  be cons idered in patie nts un dergo ing  vas cular
surgery,  ideall y  at leas t 2 weeks before  surgery.
IIa B
aClass of recommendation.
bLevel of evidence.
Table 12 – Recommendations on use of ACEIs and ARBs.
Recommendation s Clas sa Levelb
Continu ation of ACE Is or ARBs,
under close  monitori ng, sh ould be conside red  duri ng non-cardiac surgery  in stable patients  with 
heart failur e
and LV  systolic  dysfuncti on.
IIa C
Initiatio n of  ACEIs  or  ARBs  should be
considered at least 1 we ek before surger y in cardiac-s table patients wi th hear t fail ure  and LV 
systolic dysfu nctio n. IIa C
Transient  disc ontin uation  of ACE Is or
ARBs be fore non-cardiac su rgery in hype rtensive patients  sh ould be  cons ide red.
IIa C
ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; LV, left ventricular.
aClass of recommendation.
bLevel of evidence.
Table 13 – Pharmacological features of non-vitamin K antagonist oral anticoagulants.
Dabi gatran  Rivarox aban Apix aban  Edoxaban 
Target IIa(tr ombi n)  Xa  Xa  Xa 
Application Or al Or al Or al Or al 
Hours to C max  1,25 -3  2-4  3-4  1-2 
Pro-drug ye s no no no
Food interaction s  no no no no
Bioava ilability  (%)   6,5 80 -10 0  50  62 
Drug interactions 
P gp inhibi tors  or  
inductor s 
CYP3a4  inhibi tors  or  
inductor s 
P gp inhibi tors  or  
inductor s 
CYP3a4  inhibi tors  or  
inductors 
P gp inhibi tors  or  
inductors 
P gp  inhi bitor s 
Median half-t ime (h our s) 12 -14  7-11   
(11 -13  in the el dery ) 
12  6-11 
Renal clerean ce(%)  85  33  27 37 -50 
Dose regimen t  b.i.d.  q.d.  b.i.d .  q.d. 
b.i.d., bis in diem (twice daily); Cmax, maximum concentration; CYP3a4, cytochrome P3a4 enzyme; P gP, platelet glycoprotein; q.d., quaque die (once
daily).
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Table 14 – Recommendations for prophylactic revascularization in stable/asymptomatic patients.
Recommendations Class a Level b
Performance  of my ocardia l revascular izat ion  is rec ommended acc ording to the applicable guidelines
for management  in st able coron ary  arte ry disease.
I B
Late revas cular ization  aft er success ful no n-ca rdiac su rgery sh ould be considere d, in
accordance   with  ESC Guidelines on  st able coro nary artery  disease.
I C
Proph ylactic my ocardial  revascula rizat ion  before hi gh-ris k su rgery may be cons idered, depen ding on
the extent of a stre ss- in duced pe rfus ion   defect.
      IIb B
Rout ine  proph ylactic my ocardia l revasculariza tion  before low- and inte rmedia te-risk  surge ry in
patients wi th proven  IHD is not recomm ended.
      II I B
IHD, ischaemic heart disease.
aClass of recommendation.
bLevel of evidence.
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agents
4.2.1. Aspirin
For patients undergoing spinal surgery or certain neurosurgi-
cal or ophthalmological operations, it is recommended that
aspirin be discontinued for at least seven days. The use of low-
dose aspirin in patients undergoing non-cardiac surgery
should be based on an individual decision, which depends
on the perioperative bleeding risk, weighed against the risk of
thrombotic complications.
4.2.2. Dual anti-platelet therapy
The management of anti-platelet therapy should be discussed
between the surgeon and the cardiologist. Importantly, a
minimum of 1 (BMS) to 3 (new-generation DES) months of
DAPT might be acceptable, independent of the acuteness of
coronary disease, in cases when surgery cannot be delayed
for a longer period; such surgical procedures should be
performed in hospitals where 24/7 catheterization laborato-
ries are available. Independent of the timeframe between
DES implantation and surgery, single anti-platelet therapy
(preferably with aspirin) should be continued. ESC Guide-
lines recommend withholding clopidogrel and ticagrelor for
ﬁve days and prasugrel for seven days prior to surgery
unless there is a high risk of thrombosis. For patients with a
very high risk of stent thrombosis, bridging therapy with
intravenous, reversible glycoprotein inhibitors, such as
eptiﬁbatide or tiroﬁban, should be considered. The use of
low-molecular-weight heparin (LMWH) for bridging in these
patients should be avoided. Dual anti-platelet therapyshould be resumed as soon as possible after surgery and,
if possible, within 48 h.
4.2.3. Reversal of anti-platelet therapy
For patients receiving anti-platelet therapy, who have exces-
sive or life-threatening perioperative bleeding, transfusion of
platelets is recommended.
4.3. Perioperative management in patients on
anticoagulants
4.3.1. Vitamin K antagonists
If the international normalized ratio (INR) is ≤1.5, surgery can
be performed safely; however, in anticoagulated patients with
a high risk of thrombo-embolism discontinuation of VKAs is
hazardous and these patients will need bridging therapy with
unfractionated heparin (UFH) or therapeutic-dose LMWH. The
last dose of LMWH should be administered no later than 12 h
before the procedure. It is recommended that VKA treatment
be stopped 3–5 days before surgery, with daily INR measure-
ments, until ≤1.5 is reached, and that LMWH or UFH therapy be
started one day after discontinuation of VKA or later, as soon
as the INR is <2.0.
In patients with mechanical prosthetic heart valves, the
evidence in favour of intravenous UFH is more solid; thus
these patients are treated with UFH until 4 h before surgery,
and treatment with UFH is resumed after surgery until the INR
is within the therapeutic range. On the day of the procedure,
the INR should be checked. Consideration should be given to
postponing the procedure if the INR is >1.5 LMWH or UFH is
resumed at the pre-procedural dose 1–2 days after surgery,
Table 15 – Recommendations on routine myocardial revascularization in patients with NSTE-ACS.
Recommendation s Clas sa Levelb
If non-ca rdiac su rgery can  safely be po stpo ned, it is  recommended that patients  should be diagnose d
and  treated  in li ne with  the  guideli nes  on NSTE -ACS.
I A
In the unlike ly combination of
a life -thre atening clinical  conditio n re quiri ng urgent non -card iac su rgery and
revascular ization for NST E- ACS, the  exp ert te am should discuss,  case by  ca se, the  pri ority  of 
surgery.
IIa C
In patients wh o have
undergone non-c ardiac surgery,  aggressive  medical treatment  and  myocardial revasc ularizatio n 
according  to the gu idelines  on NST E-AC S
are recommended  foll owing surgery.
I B
If PCI is indicated before  semi-
urgent  su rgery, th e use  of  new -gene ration  DE S, BMS or eve n balloo n angioplasty  is re commende d.
I B
NSTE-ACS, non-ST-segment elevation acute coronary syndromes.
aClass of recommendation.
bLevel of evidence.
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12 h after the procedure. VKAs should be resumed on day 1 or 2
after surgery—depending on adequate haemostasis—with the
pre-operative maintenance dose plus a boosting dose of 50%
for two consecutive days. LMWH or UFH should be continued
until the INR returns to therapeutic levels.
Procedures with a high risk of serious bleeding complica-
tions are those where compression cannot be performed. In
these cases is warranted, discontinuation of oral anticoagu-
lants and bridging therapy with LMWH. In patients undergoing
surgery with a low risk of serious bleeding, such as cataract- or
minor skin surgery, no change in oral anticoagulation therapy
is needed; however, it is wise to keep INR levels in the lower
therapeutic range.
4.3.2. Non-vitamin K antagonist oral anticoagulants
In patients treated with dabigatran, rivaroxaban, apixaban, or
edoxaban, 'bridging' to surgery is in most cases unnecessary.
An exception to this rule is the patient with high thrombo-
embolic risk, whose surgical intervention is delayed for several
days. The overall recommendation is to stop NOACs for 2–3
times their respective biological half-lives prior to surgery insurgical interventions with 'normal' bleeding risk, and 4–5
times the biological half-lives before surgery in surgical
interventions with high bleeding risk. Reduced kidney func-
tion or moderate-to-high increased bleeding risk should lead
to earlier cessation of NOACs. If patients are pre-treated with
dabigatran, the individual glomerular ﬁltration rate deter-
mines the time of its cessation prior to surgery. Resumption of
treatment after surgery should be delayed for 1–2 (in some
cases 3–5) days, until post-surgical bleeding tendency is
diminished (Table 13).
4.3.3. Reversal of anticoagulant therapy
4.3.3.1. Vitamin K antagonists. In patients who are receiving
VKAs and who require reversal of the anticoagulant effect for
an urgent surgical procedure, low-dose (2.5–5.0 mg) intrave-
nous or oral vitamin K is recommended. If more immediate
reversal of the anticoagulant effect of VKAs is needed,
treatment with fresh-frozen plasma or prothrombin complex
concentrate is recommended, in addition to low-dose intrave-
nous or oral vitamin K.
In patients receiving UFH and requiring reversal of the
anticoagulant effect, cessation of therapy is sufﬁcient, because
c o r e t v a s a 5 7 ( 2 0 1 5 ) e 1 9 0 – e 2 1 3e202coagulation is usually normal 4 h after cessation. When UFH is
given subcutaneously, the anticoagulant effect is more
prolonged. For immediate reversal, the antidote is protamine
sulphate.
In patients who are receiving LMWHs, the anticoagulant
effect may be reversed within 8 h of the last dose. If immediate
reversal is required, intravenous protamine sulphate can be
used, but anti-Xa activity is never completely neutralized
(maximum 50%).Pati ent on  NOA C 
presenti ng wit h 
blee ding
Chec k hae modyn amic 
status, 
basic coagu lation t ests 
to ass ess  
for an  anticoagu lation  
effec t 
(e.g.  aPTT  for 
dabigatran.  etc).
renal function,  etc.
Minor
Moderate-severe
Very severe
Fig. 2 – Management of bleeding in patients taking non-vitamin
partial thromboplastin time; NOAC, non-vitamin K antagonist d
complex; rFVIIa, activated recombinant factor VII.4.3.3.2. Non-vitamin K antagonist oral anticoagulants. When
severe bleeding complications occur under the inﬂuence of
NOACs, symptomatic treatment should be initiated because of
the lack of speciﬁc antidotes. Preliminary data have shown a
potential beneﬁt for the use of PCC or activated PCC when
bleeding occurs under the direct factor Xa inhibitor rivarox-
aban, and is also applicable to apixaban and dabigatran,
whereas haemodialysis is an effective method for eliminating
dabigatran (Fig. 2).Delay  next dose or  
discontinu e tre atment
Symptomatic/supp ortive 
tre atment
Mec hanical  compress ion 
Fluid re place ment
Bloo d transfusion
Oral  charcoa l if
recently ingest ed
Considera tion of rFVlla 
or PCC
Charcoa l fil tra tion/
Haemodialysis'
 K antagonist direct oral anticoagulants. aPTT, activated
irect oral anticoagulant; PCC, prothrombin coagulation
Table 16 – Recommendations on heart failure.
Recommendation s Clas sa Levelb
It is recomm ended  that patie nts with
establi she d or suspecte d heart  fail ure,
and who  ar e sche duled  for  non-
cardiac inter mediate or high-risk surgery, undergo  ev aluation  of LV  fun ction with  tr anstho racic 
echo cardiograph y and/o r assessment  of nat riu reti c pe ptides , unles s they  hav e rec ently  been  assess ed for the se. I A
It is recomm ended  that patie nts with
establi she d he art failure, who  ar e scheduled for inte rmediat e or  high-  ris k non- cardiac surgery, be  
ther apeutically optimize d as  necess ary, using beta -blocke rs, AC EIs or ARB s, and mineralocorticoid
ant agoni sts and diur etic s, acc ordi ng to
ESC Guidelin es for heart fail ure  treatmen t.
I A
In pat ients with newly diagnosed he art
failure,  it is recommended th at intermediate- or hi gh-risk surg ery be  deferr ed, preferab ly for at le ast 3  months  
afte r initia tion of he art failure  ther apy, to allow time for ther apy up- tit ration and poss ible  improvem ent of LV 
functi on.
I C
It is recommen ded that beta blockade
be cont inue d in hea rt failure patients th roughout the pe ri- ope rati ve pe riod,  where as ACEIs/ ARBs ma y be 
omitt ed
on the morning of surgery , takin g into
con siderat ion the pat ient’s bloo d pressure. If  ACEIs/ARBs  ar e given , it is  import ant to caref ully monito r the 
patient 's hae mod ynamic status and
give app ropriat e volume rep lacement  when  necess ary.
I C
Unless there is adequate  time  for
dose-titration, initiation  of hi gh-dose  be ta-blockade be fore non-c ard iac surgery  in  patients  with  hea rt failure  is 
not rec ommended . III B
ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; LV, left ventricular.
aClass of recommendation.
bLevel of evidence.
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Indications for pre-operative coronary angiography and
revascularization, in patients with known or suspected IHD
who are scheduled for major non-cardiac surgery, are similar
to those in the non-surgical setting.
4.4.1. Prophylactic revascularization in patients with
asymptomatic or stable ischaemic heart disease
In asymptomatic patients or those with stable CAD, prophy-
lactic coronary angiography—and, if needed, revascularization
before non-cardiac surgery—does not confer any beneﬁcialeffects as compared with optimal medical management.
Myocardial revascularization may be recommended in
patients presenting with persistent signs of extensive ischae-
mia before elective non-cardiac surgery similar to non-surgical
settings.
4.4.2. Type of prophylactic revascularization in patients with
stable ischaemic heart disease
Occasionally, patients with stable IHD may require elective
surgery. It seems reasonable to propose a cardiovascular work-
up according to the ESC Guidelines on stable angina pectoris
(Table 14).
c o r e t v a s a 5 7 ( 2 0 1 5 ) e 1 9 0 – e 2 1 3e2044.4.3. Revascularization in patients with non-ST-elevation
acute coronary syndrome
If the clinical condition requiring non-cardiac surgery is not life-
threatening, priority should be given to the management of
NSTE-ACS. Inthe rare scenario of NSTE-ACS linked with theneed
for subsequent early non-cardiac surgery, at the time of PCI,
preference should be given either to BMS, or to new-generation
DES if data from recent trials conﬁrm non-inferiority. Balloon
angioplasty alone may be a reasonable strategy (Table 15).
5. Speciﬁc diseases
5.1. Chronic heart failure
In patients with newly diagnosed severe systolic heart failure,
it is recommended that non-urgent surgery be deferred for at
least three months. Patients with heart failure should
preferably be euvolemic before elective surgery, with stable
blood pressure and optimal end-organ perfusion.
Patients with HF-PEF have an increased stiffness of the left
ventricle and are susceptible to pulmonary oedema with ﬂuid
overload. Adequate perioperative monitoring, attention to
volume status, control of afterload, and adequate diuretic
treatment are important considerations for these patients.
Post-operative heart failure often presents atypically and
may have a different aetiology from the non-surgical setting
(Table 16).
5.2. Arterial hypertension
When raised blood pressure is discovered in a pre-operative
evaluation, it is advisable to search for target organ damageTable 17 – Recommendations on arterial hypertension.
Recomm endati ons
It is rec ommen ded th at patients  with a new diag nosis of hype rt
be screened   for end-o rgan damag e  and ca rdiovasc ular  risk
factors.
Large peri- operative  fluctu ations  in  blood  pressu re in hyperten
be avoided .
Cli nici ans  may consider   not deferrin g no n-car dia c  surger y in pa
hypertension  (sys tolic  blood  pressu re  <18 0 mm  Hg; diastolic  b
Hg).
aClass of recommendation.
bLevel of evidence.and evidence of associated cardiovascular pathology, and to
initiate therapy to lower the blood pressure to an appropriate
level. In patients with grade 1 or 2 hypertension (systolic blood
pressure <180 mmHg; diastolic blood pressure <110 mmHg)
there is no evidence of beneﬁt from delaying surgery to
optimize therapy. In patients with grade 3 hypertension, the
potential beneﬁts of delaying surgery to optimize the
pharmacological therapy should be weighed against the risk
of delaying the procedure (Table 17).
5.3. Valvular heart disease
5.3.1. Patient evaluation
In patient with severe VHD is recommended clinical and
echocardiographic evaluation, if necessary treatment should be
initiated treatment VHD before noncardiac surgery.
5.3.2. Aortic stenosis
In symptomatic patients, aortic valve replacement should be
considered before elective surgery. In patients who are not
candidates for valve replacement, non-cardiac surgery should
be performed only if is essential. In patients at high risk or
contra-indicated for aortic valve replacement, balloon aortic
valvuloplasty or, preferably, transcatheter aortic valve im-
plantation may be a reasonable therapeutic option before
surgery. In asymptomatic patients, non-cardiac surgery of low
to intermediate risk can be performed safely.
5.3.3. Mitral stenosis
Non-cardiac surgery can be performed with relatively low
levels of risk in patients with non-signiﬁcant mitral stenosis
and in asymptomatic patients with signiﬁcant mitral stenosis
and systolic pulmonary artery pressure <50 mmHg.Classa Levelb
ens ion pre- operatively
I C
sive  patient s sh ould
IIa B
tie nts with grade 1 or 2
loo d press ure  <110 mm 
IIb B
Table 18 – Recommendations on VHD.
Recommen datio n aClas s bLevel
Clinical an d
echocardiog raphi c
evaluat ion is
recomm end ed in all
patients wit h known or
suspected VHD, who are
schedu led for ele cti ve
interme dia te or high-r isk
non-cardiac surgery.
I C
Aortic valve repl aceme nt
is recomm ended in
symptom ati c patients wit h
severe ao rti c stenos is,
who are schedu led for
elective no n-cardiac
surgery, provided that
they are no t at high risk
of an adverse ou tcome
from for valvular surgery.
I B
Aortic valve repl aceme nt
sho uld be considered in
asympt omat ic patients
with severe aorti c
stenosi s, wh o are
schedu led for ele cti ve
high -ri sk no n-cardi ac
surgery, provided that
they are no t at high risk
of an adverse ou tcome
from for valvular surgery.
IIa C
In sympto matic pati ents
with severe aorti c
stenosi s wh o are
schedu led for ele cti ve
non-cardiac surgery, TAVI
or balloo n ao rti c
valvuloplasty shoul d be
considered by the exp ert
team if they are at high
risk of an ad verse
outcom e from fo r valvular
surgery.
IIa C
Electiv e non-cardiac
surgery sho uld be
considered in patients
with severe valvular
regu rgitation, who do no t
have severe heart failu re
or LV dy sfun ction.
IIa C
Percut aneous mitra l
commiss urotomy sho uld
be co nsid ered in patients
with severe mi tral
stenosi s, wh o hav e
symp toms of pu lmonary
hypertensi on and are
schedu led for ele cti ve
interme dia te- or high-ri sk
non-cardiac surgery.
IIa C
LV, left ventricular; TAVI, transcatheter aortic valve implantation;
VHD, valvular heart disease.
aClass of recommendation.
bLevel of evidence.
c o r e t v a s a 5 7 ( 2 0 1 5 ) e 1 9 0 – e 2 1 3 e2055.3.4. Primary aortic regurgitation and mitral regurgitation
In asymptomatic patients with severe aortic or mitral
regurgitation and preserved LV function, non-cardiac surgery
can be performed without additional risk. Symptomatic
patients—and those who are asymptomatic with severely
impaired LVEF (<30%)—are at high risk of cardiovascular
complications, and non-cardiac surgery should be performed
only if necessary.
5.3.5. Secondary mitral regurgitation
Patients should undergo perioperative evaluation and man-
agement according to the recommendations for LV systolic
dysfunction and, if secondary mitral regurgitation is due to
IHD, those for IHD.
5.3.6. Patients with prosthetic valve(s)
Patients who have a prosthetic valve can undergo non-cardiac
surgery without additional risk, provided that there is no
evidence of valve or ventricular dysfunction.
5.3.7. Prophylaxis of infective endocarditis
Indications for antibiotic prophylaxis are limited to high-risk
patients undergoing dental care; however, non-speciﬁc pro-
phylaxis remains recommended in all patients at intermediate
or high risk of infective endocarditis (Table 18).
5.4. Arrhythmias
Cardiac arrhythmias are a signiﬁcant cause of morbidity and
mortality in the peri-operative period.
5.4.1. New-onset ventricular arrhythmias in the pre-operative
period
Ventricular arrhythmias, including ventricular premature
beats (VPBs) and ventricular tachycardia (VT) are particularly
common in high-risk patients. Polymorphic VT is a common
result of acute myocardial ischaemia. Treatment steps for
VPBs include identifying and correcting the reversible causes
(e.g. hypoxia, hypokalemia and hypomagnesaemia).
Sustained monomorphic VT with haemodynamic compro-
mise must be treated promptly with electric cardioversion.
Intravenous amiodarone can be used for initial treatment of
patients with stable sustained monomorphic VT, to prevent
recurrences. Immediate deﬁbrillation is required to terminate
ventricular ﬁbrillation and sustained polymorphic VT. Beta-
blockers are useful in patients with recurrent sustained
polymorphic VT. Detection of these arrhythmias preopera-
tively should therefore lead to diagnostic evaluation and
appropriate therapy (Table 19).
5.4.2. Management of supraventricular arrhythmias and
atrial ﬁbrillation in the pre-operative period
Supraventricular arrhythmias and AF are more common than
ventricular arrhythmias in the peri-operative period. Possible
aggravating factors such as respiratory failure or electrolyte
imbalance should also be corrected. In cases with commonly
recurring SVT in the peri-operative setting, beta-blockers,
calcium channel blockers, or amiodarone can be used. The
objective in managing peri-operative AF is usually ventricular
rate control. Beta-blockers and calcium channel blockers are
Table 19 – Recommendations for ventricular arrhythmias.
Recommendati ons a b
Continu ation  of oral ant i-
arrhythmic drugs  bef ore  sur gery  is recommended. I C
Electrical   cardioversion when
haemod ynamic in stabili ty occurs is recommende d. I C
Vaga l manoeu vres  and ant i-
arrhythmic th erapy  for termination of  SVT  in haemodynamicall y  stab le 
patie nts  is recommended. I C
Class Level
VT, ventricular tachycardia; VPB, ventricular premature beats.
aClass of recommendation.
bLevel of evidence.
Table 20 – Recommendations on supraventricular ar-
rhythmias.
Recommendati ons      Class  a Level b
Continu ation  of oral ant i-
arrhythmic drugs  bef ore  sur gery  is recommended. I C
Electrical  cardi oversion when
haemod ynamic in stabili ty occurs is recommende d. I C
Vaga l manoeu vres  and ant i-
arrhythmic th erapy  for termination of  SVT  in haemodynamically  stab le 
patients  is recommended. I C
SVT, supraventricular tachycardia.
aClass of recommendation.
bLevel of evidence.
c o r e t v a s a 5 7 ( 2 0 1 5 ) e 1 9 0 – e 2 1 3e206the drugs of choice for rate control. Amiodarone can be used as
a ﬁrst-line drug in patients with heart failure (Table 20).
5.4.3. Peri-operative bradyarrhythmias
Peri-operative bradyarrhythmias usually respond well to
short-term pharmacological therapy; temporary cardiac pac-
ing is rarely required. Prophylactic pacing before non-cardiac
surgery is not commonly indicated (Table 21).Table 21 – Recommendations on bradyarrhythmias and pacem
Recomm endati ons 
The indications for temporary
pacemaker s during the peri- opera tiv e per iod are  gener all y th
permanent pa cemaker s.
It is rec ommend ed that the hospital
nominate a pe rson wh o is re sponsible  for pr ogram ming  of t
devices before and after  surgery.
Patients  wi th ICDs,  whose  devices  have
been pre -operatively dea ctivated , should be  on cont inu ous ca 
thr ough out the period  of  de activa tion. Ex ternal de fibrillati on 
readily availabl e.
Patients  who have asy mptomatic
bifasc icular  or tri fascic ular  bl ock are  not  re commended  for ro
with a peri -opera tive temp orar y pacing  wire .
aClass of recommendation.
bLevel of evidence.5.4.4. Peri-operative management of patients with
pacemaker/implantable cardioverter deﬁbrillator
Patients with a permanent pacemaker can undergo surgery if
appropriate precautions are taken. The use of unipolar
electrocautery represents a signiﬁcant risk, as the electrical
stimulus from electrocautery may inhibit 'demand' pace-
makers, or may reprogram the pacemaker. These problems
can be avoided or minimized by using bipolar electrocautery,akers.
Classa Levelb
e same  as those for 
I C
he impl anted arrh ythmia  
I C
rdiac monitor 
equipment shou ld be 
I C
utine  managemen t 
III C
Table 22 – Recommendations on renal function.
CI-AKI, contrast-induced acute kidney injury; CKD, chronic kidney
disease; GFR, glomerular ﬁltration rate; IOMC, iso-osmolar contrast
medium; LOCM, low-osmolar contrast medium.
aClass of recommendation.
bLevel of evidence.
c o r e t v a s a 5 7 ( 2 0 1 5 ) e 1 9 0 – e 2 1 3 e207correct positioning the ground plate for the electrical circuit.
The pacemaker should be set in an asynchronous or non-
sensing mode in patients who are pacemaker-dependent.
Interference with the function of implantable cardioverter
deﬁbrillators (ICD) can also occur during non-cardiac surgery.
The ICD should be turned off during surgery and switched on
in the recovery phase before discharge to the ward.
5.5. Renal disease
Impaired renal function is associated with a signiﬁcantly
increased risk of CVD and is an independent risk factor for
adverse post-operative cardiovascular outcomes, including
myocardial infarction, stroke, and progression of heart failure.
The development of acute kidney injury (AKI) after major
surgery reduces long-term survival in patients with normal
baseline renal function (Table 22).
5.6. Cerebrovascular disease
With non-cardiac surgery, peri-operative stroke has been
reported in 0.08–0.7% of patients undergoing general surgery.
Peri-operative strokes are mainly ischaemic and cardioembolic
and AF is often the underlying leading condition. Patients
undergoing non-cardiac surgery should be questioned about
previous neurological symptoms, and those with symptoms
suggestive of TIA or stroke in the preceding 6 months should
undergo pre-operative neurological consultation as well as
neurovascular and brain imaging. Carotid imaging, while not
indicated routinely in patients undergoing non-cardiac surgery,
may be considered before vascular surgery, due to the high
prevalence of carotid artery disease in this patient group.
To attenuate the risk of peri-operative stroke, anti-platelet/
anticoagulant treatments should be continued whenever
possible throughout the peri-operative period. Adequate selec-
tion of the anaesthetic technique, prevention and treatment of
AF, euglycaemic control, as well as meticulous peri-operative
blood pressure control, may all contribute to reducing the risk of
peri-operative stroke.
In patients with symptomatic carotid disease, carotid
revascularization should perform ﬁrst and non-cardiac sur-
gery postponed (Table 23).
5.7. Peripheral artery disease
Patients with PAD usually have advanced atherosclerotic
disease affecting most vascular beds in varying degrees and
have a worse prognosis than patients without PAD. It is
reasonable to access the presence of IHD from the patient's
history and routine clinical examinations and tests. All
patients with PAD should be treated with statins and platelet
inhibitors.
5.8. Pulmonary disease
The co-existence of pulmonary disease in patients undergoing
non-cardiac surgery may increase the operative risk. Such
diseases include acute respiratory infections, COPD, asthma,
cystic ﬁbrosis, interstitial lung disease, and other conditions
causing impairment of respiratory function.
Table 23 – Recommendations on patients with suspected or established carotid artery disease.
Recomm endati ons a b
Pre-oper ative  carot id arte ry and
cerebral imaging  are recommen ded  in
pati ents wit h a history of TI A or  stroke  in the  preced ing  6 month s. I C
Pre-oper ative, routine  car otid arter y
imag ing  ma y be  considered  in pa tien ts un derg oing  vasc ular  surger y. IIb C
Whenever  possible,  continua tion of
anti- platelet  and stati n therap ies should be  considered  thr ough out the peri-  
operative  ph ase in patients  wit h carotid artery  disease. IIa C
For patients wit h carotid ar tery dise ase
undergoi ng non-cardiac  surgery, the  same indicat ions fo r caro tid 
revascul ari zati on sh ould app ly as for the genera l popu lation. IIa C
Pre-oper ative  routine  car otid  arter y
imag ing  is not recommended  in pa tien ts unde rgoing  non-vascular  
surgery. III C
Class Level
TIA, transient ischaemic attack.
aClass of recommendation.
bLevel of evidence.
c o r e t v a s a 5 7 ( 2 0 1 5 ) e 1 9 0 – e 2 1 3e208Beta-adrenergic agonists and anticholinergic agents
should be continued until the day of surgery in all symptom-
atic COPD patients with bronchial hyper-reactivity. In some
cases, short-term systemic/inhaled steroids may be consid-
ered.
Pulmonary artery hypertension (PAH) is associated
with increased post-operative complications, including
right ventricular failure, myocardial ischaemia, and post-
operative hypoxia. Ideally, patients with PAH should have
an optimized treatment regimen before any surgical
intervention, and be managed in a centre with appropriate
expertise (Table 24).
5.9. Congenital heart disease
Children, adolescents and adults with congenital heart
disease are generally regarded as being at increased risk
when undergoing non-cardiac surgery but this risk will vary
enormously, according to the degree of associated
heart failure, pulmonary hypertension, arrhythmias, and
shunting of blood—with or without associated oxygen
desaturation and by the complexity of the underlyingcondition. Complicated patients with congenital heart
disease should only undergo non-cardiac surgery after
thorough evaluation by a multidisciplinary team in a
specialized centre (Table 25).
6. Peri-operative monitoring
6.1. Electrocardiography
Continuous ECG monitoring is recommended for all patients
undergoing anaesthesia (Table 26).
6.2. Transoesophageal echocardiography
Transoesophageal echocardiography (TOE) may also be useful
if acute and severe haemodynamic instability or life-threat-
ening abnormalities develop during or after surgery. TOE can
be useful in the operating room in patients with severe
valvular lesions. The value of TOE for systematic haemody-
namic monitoring in patients at risk is more controversial
(Table 27).
Table 24 – Recommendations on PAH and pulmonary diseases.
Recomm endati ons Clas sa Levelb
It is  re commended  that patients  with
severe PAH , who are  un der going  elect ive surgery,  be  managed  in  a cen tre  wit h 
appr opriate ex per tise. I C
It is  re commended  that inter ventions
for hi gh-ri sk patients wi th PAH  be  pl anne d by the mul tidisciplin ary pulm onary 
hyper tensi on team. I C
It is  re commended  that patients  with
PAH ha ve an  optimized  trea tmen t reg imen be fore  any non-emergency  surg ical 
interve ntion. I C
It is  re commended  that patients
receiving PAH-spe cif ic treatment c ontinue  thi s in  the  pre-,  peri-,  and post-
opera tive peri od wi thout in ter rup tion. I C
It is  re commended  that monit orin g
of pa tient s wi th PAH  continue  for at  lea st 24  hour s in  the  post-oper ati ve peri od.
I C
In the case  of  progressi on of  rig ht
heart failure  in  the post-oper ativ e peri od of patien ts wi th PAH,  it  is 
recommended  that the diur etic dose be  optimized  and , if ne ces sary,  intraven ous 
vasoactive drugs be  initiated  under  the gu idan ce of a ph ysician  exper ien ced  in the 
managemen t of PAH . I C
In patie nts wit h COPD,  smoking
cess ation (>2  months be fore  surger y)  is re commended  be fore  unde rtakin g 
surger y. I C
In the case  of  severe  right he art
failure  that is no t responsiv e to supp ortive ther apy,  the temporar y admini stration 
of pulm onar y vasodilato rs (inh aled  and/o r in tra ven ous)  is re commended,  under  
the guidance  of  a  physic ian experien ced in  PAH.
I C
In patie nts  at high  ri sk of OHS
additional  specialis t investigat ion before  maj or ele ctive  surgery  sh ould  be  
considered. IIa C
PAH, pulmonary artery hypertension; OHS, obesity hypoventilation syndrome.
aClass of recommendation.
bLevel of evidence.
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Table 25 – Recommendation on patients with congenital heart disease.
t
Recomm endatio n Class a bLevel
It is  re comme nded  that,  pa ie nts  with  comp lex   congenital he art disease be  referre d for
additional specialis t inve stiga tion be fore unde rgoing  elective  non -cardiac su rgery,  if feasibl e. I C
aClass of recommendation.
bLevel of evidence.
Table 26 – Recommendations on ECG monitoring.
Recomm endati ons Classa Levelb
Peri- ope rative  ECG  monitoring is  recommended for all patients  undergoi ng
surgery. I C
Selected le ad combi nations shou ld be
considered   for bett er detect ion
of is chaemia  in the opera ting  roo m.
IIa B
When feas ible,  twelve-le ad ECG
monitori ng shou ld be  considered for  high-risk  patients  undergo ing surgery .
IIa B
ECG, electrocardiogram.
aClass of recommendation.
bLevel of evidence.
Table 27 – Recommendations on intra-operative and/or
peri-operative TOE for detection of myocardial ischaemia.
ECG, electrocardiogram; TOE, transoesophageal echocardiography.
aClass of recommendation.
bLevel of evidence.
c o r e t v a s a 5 7 ( 2 0 1 5 ) e 1 9 0 – e 2 1 3e2106.3. Right heart catheterization
Routine PAC and right heart monitoring is therefore not
recommended in patients during non-cardiac surgery.
6.4. Disturbed glucose metabolism
Surgery in patients with diabetes is associated with longer
hospital stay, higher healthcare resource use, and greater peri-
operative mortality. Critical illness is also characterized by
dysglycaemia, which may develop in the absence of previously
diagnosed diabetes, and has repeatedly been identiﬁed as an
important risk factor for morbidity and mortality. Hypergly-
caemia has adverse effect on renal and hepatic function,
endothelial function, and immune response Minimization of
the degree of glucose variability may be cardioprotective.
6.5. Anaemia
In emergency surgery, transfusion may be needed and should
be given according to clinical needs. In elective surgery, a
symptom-guided approach is recommended.
Fig. 3 – Summary of pre-operative cardiac risk evaluation and perioperative management. ACEI, angiotensin converting
enzyme inhibitor; CABG, coronary artery bypass graft; DES, drug-eluting stent; ECG, electrocardiogram; IHD, ischaemic heart
disease; MET, metabolic equivalent.
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Table 28 – Recommendations on anaesthesia.
Recomm endati ons Clas sa Levelb
Patients  wit h high cardiac  and surgical  risk  should be
cons idered  for goal-directed  ther apy.
IIa B
The measur ement of
natriur etic  peptides and hi gh- sensitivity  troponin after  surgery  may  be 
considered  in high -risk  patients  to impr ove ri sk str atific ati on.
IIb B
Neuraxial ana est hesia (alon e),
in the  absence  of contra-  in dicati ons and  after  es timation of the  ri sk–ben efi t 
ratio, re duces  the  risk of  pe ri-  operative  mortali ty and morbidity  compared 
with general  an aesthesia  and  ma y
be considered . IIb B
Avoidin g arteri al hypotension
(mean  ar ter ial pre ssure  <60  mm  Hg ) for pr olonged  cumulativ e pe riods (>30  
minu tes) ma y be  considered . IIb B
Neuraxial an alges ia, in th e
absen ce of contra-indi cations, ma y be  considered  to  pr ovide post-opera tiv e 
analges ia. IIb B
Avoidin g non-steroidal an ti-
inflam mator y dr ugs (especial ly cyclo-oxyge nase- 2 inh ibitors) a s the fi rst-li ne 
analgesics in patients  with  IH D or stroke  may be  considere d. IIb B
IHD, ischaemic heart disease.
aClass of recommendation.
bLevel of evidence.
c o r e t v a s a 5 7 ( 2 0 1 5 ) e 1 9 0 – e 2 1 3e2127. Anaesthesia
The optimal peri-operative course for high-risk cardiovas-
cular patients should be based on close co-operation
between cardiologists, surgeons, pulmonologists, and
anaesthesiologists. Pre-operative risk assessment andpre-operative optimization of cardiac disease should be
performed jointly.
7.1. Intra-operative anaesthetic management
There is conﬂicting evidence whether a speciﬁc anaesthetic
agent is superior in patients with cardiac disease, with the
c o r e t v a s a 5 7 ( 2 0 1 5 ) e 1 9 0 – e 2 1 3 e213suggestion that volatile anaesthetic agents offer better
cardioprotection than intravenous agents.
7.2. Neuraxial techniques
Neuraxial anaesthesia (spinal or epidural) has not systemati-
cally decreased the risk of myocardial infarction or mortality
but associated with a lower risk of other complications and
may be considered for the management of patients with
cardiovascular risk factors or diseases without contraindica-
tions. Cardiac patients are often on various types of drugs
interfering with coagulation and care should be taken to
assure sufﬁcient coagulation ability when neuraxial blocks are
applied.
7.3. Peri-operative goal-directed therapy
Goal-directed therapy aims to optimize cardiovascular perfor-
mance, in order to achieve normal or even supranormal
oxygen delivery to tissues, by optimizing pre-load and
inotropic function using predeﬁned haemodynamic goals.
Goal-directed therapy is based on ﬂow or ﬂuid responsiveness
of haemodynamic variables.
7.4. Risk stratiﬁcation after surgery
Recent studies have demonstrated that it is possible to stratify
the risk of post-operative complications and mortality with a
simple surgical 'Apgar' score. This post-event stratiﬁcation
might allow redirecting patients to higher intensity units.
7.5. Early diagnosis of post-operative complications
Pre-operatively and post-operatively, patients who could most
beneﬁt from BNP or high-sensitivity troponin measurements
are those with METs ≤4 or with a revised cardiac risk index
value >1 for vascular surgery and >2 for non-vascular surgery.
Post-operatively, patients with a surgical Apgar score <7should also be monitored with BNP or high-sensitivity
troponin measurements.
7.6. Post-operative pain management
Severe post-operative pain, reported in 5–10% of patients,
increases sympathetic drive and delays recovery. Neuraxial
analgesia with local anaesthetics, or opioids and/or alpha2-
agonists, and intravenous opioids, alone or in combination
with non-steroidal anti-inﬂammatory drugs, seem to be the
most effective regimens (Table 28).
8. Summary
Fig. 3 presents, in algorithmic form, an evidence-based,
stepwise approach for determining which patients beneﬁt
from cardiac testing, coronary artery revascularization, and
cardiovascular therapy before surgery.
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